SPARC and glioblastoma: Benefitting from the specific recognition of the albumin and SPARC and gp60 receptors on the BBB endothelium and GBM cell surface as well as the recognition of iRGD with the overexpressed αvβ3 and αvβ5 integrins on the GBM cells, the obtained nanomedicine could cross the BBB and be distributed throughout the tumor volume without the use of invasive surgical procedures via intravenous (i.v.)injection.